GREY:IPHAF - Post by User
Post by
intrepidcdnon Nov 05, 2003 8:46pm
403 Views
Post# 6609603
ISA - Stocktalk Presentation
ISA - Stocktalk PresentationI'm not sure if anyone else from this board attended the Stocktalk get together in Edmonton yesterday or if those who attended felt that Dr. Yatscoff had nothing worth repeating; hence no related posts . I attended his session(and spoke to him at the company booth afterwards) and gleamed abit of what I considered new information that is worth sharing. This is my interprepation:
-Isotechnikas share of the 'profits' from sales of ISA 247 will be a low of 14% and a high of 40%.This part of the Agreement is based on a "sliding" scale. The larger ISA's market share, the higher Isotechnikas take. As we are aware, Roche covers the production and marketing costs.
-Assuming all goes well in the testing etc.,the drug should be on the market for psoriasis patients before it is available for transplant patients.
-A number of U.S. analysts are reviewing the Isotechnika story and are expected to release their reports early next year.
Dr. Yatscoff confirmed that the companies goal is to to be listed on the NASDAQ next year. I found all of this information to be quite reassuring.If anyone else on the board attended and has a interpretation that is different then mine or wants to add information, please feel free to do so.